CD19 and neoplasm: Moreover, regardless of costimulation from the tumor cell, anti-CD19 AbTCR-T cells had similar anti-tumor activity compared to CAR-T cells in both Raji (Figs. 3c, 5a, b, Supplementary Fig. S4) and CD80-/CD86- (Figs. 3c, 5b, c) tumor models.